Silverback Therapeutics, ARS Pharmaceuticals enter into merger agreement
Silverback Therapeutics, ARS Pharmaceuticals enter into merger agreement
1.49BUSD
See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US82835W1080
CUSIP
82835W108
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-
Book Value
2.33
Dividend Share
-
Dividend Yield
-
Earnings Share
-0.16
Wall Street Target Price
31.60
EPS Estimate Current Year
-1.55
EPS Estimate Next Year
-0.72
EPS Estimate Current Quarter
-0.3625
EPS Estimate Next Quarter
-0.4475
Most Recent Quarter
-
Revenue TTM
97,122,000
Gross Profit TTM
77,753,000
EBITDA
-26,720,000
Profit Margin
-16.11%
Return On Assets TTM
-6.10%
Return On Equity TTM
-6.91%
Revenue Per Share TTM
0.998
Qtly Revenue Growth YOY
4900.00%
Diluted Eps TTM
-0.16
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
0
Price Sales TTM
14.9866
Price Book MRQ
6.3567
Enterprise Value Revenue
12
Enterprise Value EBITDA
-9
313.25
1.42%447.40
1.22%513.01
0.81%542.04
0.24%586.54
0.00%90.46
-3.20%190.02
-2.85%148.56
-1.54%252.80
-0.50%78.18
-0.37%